UY38999A - Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos - Google Patents

Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos

Info

Publication number
UY38999A
UY38999A UY0001038999A UY38999A UY38999A UY 38999 A UY38999 A UY 38999A UY 0001038999 A UY0001038999 A UY 0001038999A UY 38999 A UY38999 A UY 38999A UY 38999 A UY38999 A UY 38999A
Authority
UY
Uruguay
Prior art keywords
protein tyrosine
tyrosine phosphatase
methods
degraders
same
Prior art date
Application number
UY0001038999A
Other languages
English (en)
Inventor
E Kort Michael
Gesine Kerstin Veits
Mark E Fitzgerald
Alexander W Hird
James A Henderson
Harit U Vora
Ramzi F Sweis
G Nasveschuk Christopher
Martin Duplessis
Original Assignee
Abbvie Inc
Calico Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Calico Life Sciences Llc filed Critical Abbvie Inc
Publication of UY38999A publication Critical patent/UY38999A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En el presente documento se proporcionan compuestos, composiciones y métodos útiles para degradar la proteína tirosina fosfatasa, por ejemplo, proteína tirosina fosfatasa no receptora tipo 2 (PTPN2) y / o proteína tirosina fosfatasa no receptora tipo 1 (PTPN1), y para el tratamiento favorable de enfermedades relacionadas. sensibles al tratamiento con inhibidores de PTPN1 o PTPN2, por ejemplo, un cáncer o una enfermedad metabólica.
UY0001038999A 2019-12-20 2020-12-21 Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos UY38999A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962952097P 2019-12-20 2019-12-20
US201962952161P 2019-12-20 2019-12-20
US202063121721P 2020-12-04 2020-12-04
US202063125937P 2020-12-15 2020-12-15

Publications (1)

Publication Number Publication Date
UY38999A true UY38999A (es) 2021-07-30

Family

ID=74206162

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038999A UY38999A (es) 2019-12-20 2020-12-21 Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos

Country Status (8)

Country Link
EP (1) EP4077319A1 (es)
JP (1) JP2023508914A (es)
CN (1) CN116194453A (es)
AU (1) AU2020407244A1 (es)
CA (1) CA3162364A1 (es)
TW (1) TW202136250A (es)
UY (1) UY38999A (es)
WO (1) WO2021127586A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202109024YA (en) 2019-04-12 2021-09-29 C4 Therapeutics Inc Tricyclic degraders of ikaros and aiolos
US20230167081A1 (en) * 2020-04-30 2023-06-01 President And Fellows Of Harvard College 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders
CN116648248A (zh) * 2021-01-26 2023-08-25 成都茵创园医药科技有限公司 芳香化合物、含其的药物组合物及其应用
AU2022268977A1 (en) 2021-05-05 2023-11-30 Biogen Ma Inc. Compounds for targeting degradation of bruton's tyrosine kinase
WO2022271727A1 (en) * 2021-06-21 2022-12-29 Calico Life Sciences Llc Degrader compounds and uses thereof
UY39844A (es) 2021-07-07 2023-01-31 Biogen Ma Inc Compuestos para la degradación selectiva de las proteínas irak4
EP4384512A1 (en) * 2021-08-10 2024-06-19 Calico Life Sciences LLC Protein tyrosine phosphatase targeting ligands
CN118201923A (zh) * 2021-10-15 2024-06-14 海南先声再明医药股份有限公司 三环类化合物
TW202333670A (zh) * 2022-01-04 2023-09-01 大陸商海思科醫藥集團股份有限公司 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用
TW202415665A (zh) * 2022-06-06 2024-04-16 美商樹線生物科學公司 三環喹啉酮ｂｃｌ６雙功能降解劑
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
EP3455218A4 (en) * 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
IL273432B (en) * 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses

Also Published As

Publication number Publication date
CA3162364A1 (en) 2021-06-24
EP4077319A1 (en) 2022-10-26
WO2021127586A1 (en) 2021-06-24
JP2023508914A (ja) 2023-03-06
TW202136250A (zh) 2021-10-01
CN116194453A (zh) 2023-05-30
AU2020407244A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
UY38613A (es) Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos
CO2021000447A2 (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112019003866A2 (pt) adenovírus estimulado com fragmento de mab biespecífico com redirecionamento de células t (bite)
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CL2019000732A1 (es) Tratamiento avv de la enfermedad de huntington.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
CL2023000524A1 (es) Compuestos fosfolípidos y usos de los mismos
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
CO2022000270A2 (es) Inhibidores de enzimas
NI202000085A (es) Moduladores de la expresión de apol1
EA202092487A1 (ru) Ферменты кинурениназы человека и их применение
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CO2022000266A2 (es) Inhibidores de enzimas
CL2023001062A1 (es) Compuestos fosfolípidos y usos de estos
CO2021007006A2 (es) Moduladores de la expresión de irf5
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
CO2022014499A2 (es) Moduladores de nlrp3
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.